HGF and neoplasm: Rather than using a ‘one size fits all’ approach however, we propose first that a biomarker such as high HGF concentrations in ascites, or high c-MET/phosphorylated c-MET in tumour samples, be used to select patients for therapy with small molecule c-MET inhibitors.